Clinical Safety And Protective Efficacy After Immunization With Genetically Modified Plasmodium Berghei Sporozoites Expressing P. Falciparum Circumsporozoite Protein In A First-In-Human Phase1/2A Trial
AuthID
P-00R-M3X
P-00R-M3X